The results of the RECOVER-LV clinical trial were published online in Circulation on 14 May 2021, following their presentation as a Late Breaking Clinical Trial at the Heart Failure Society of America Annual Scientific Meeting in October 2020.

Photo of woman experiencing chest or heart pain

The Robertson Centre for Biostatistics (Bethany Stanley, Alex McConnachie) supported the trial, led by staff from the BHF Glasgow Cardiovascular Research Centre in UofG's Institute of Cardiovascular and Medical Sciences.

The trial found that the addition of neprilysin inhibition to standard therapy did not have a substantial effect on late left ventricular remodelling in asymptomatic patients with left ventricular systolic dysfunction after myocardial infarction, but may have a beneficial effect in more selected patients with elevated natriuretic peptides, a marker of increased left ventricular wall stress.

Read the paper

First published: 24 May 2021

<< News stories from 2021